Does Medicare Advantage Cover Jardiance (Empagliflozin)?

How Medicare Advantage Prescription Drug Coverage Works for Jardiance

Medicare Advantage (Part C) plans that include Part D prescription benefits follow formulary rules set by the plan sponsor, but those rules must comply with CMS (Centers for Medicare & Medicaid Services) guidelines. Each plan maintains its own formulary, a list of covered medications organized into tiers that determine your out-of-pocket cost.

Formulary Tier Placement

Jardiance lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) in the majority of Medicare Advantage Part D formularies. Tier 3 placement typically means copays of $35 to $47 per month, while Tier 4 placement can push copays to $80 to $100 or higher depending on the plan. A small number of plans place Jardiance on a specialty tier (Tier 5), which may involve coinsurance of 25% to 33% rather than a flat copay.

CMS requires all Part D plans to cover at least two drugs per pharmacologic class. Because SGLT2 inhibitors represent a distinct class, plans must include empagliflozin or a therapeutic alternative like dapagliflozin (Farxiga) or canagliflozin (Invokana). This means even if Jardiance is listed as non-preferred, an SGLT2 inhibitor will appear on every Medicare Advantage formulary.

Why the Specific Plan Matters

No two Medicare Advantage plans are identical. UnitedHealthcare AARP plans, Humana Gold Plus, Blue Cross Blue Shield Medicare Advantage, Aetna Medicare, and Cigna-HealthSpring each negotiate different rebate structures with Boehringer Ingelheim (the manufacturer). Those rebates directly influence tier placement. Check your plan's formulary on Medicare.gov or call the number on your member ID card before assuming coverage terms.

Prior Authorization Requirements for Jardiance on Medicare Advantage

Prior authorization (PA) is the single biggest barrier between a Jardiance prescription and pharmacy pickup. Most Medicare Advantage plans require PA for empagliflozin regardless of indication.

What the PA Process Looks Like

Your prescribing clinician submits documentation to the plan confirming one of three FDA-approved indications: type 2 diabetes mellitus, heart failure (HFrEF or HFpEF), or chronic kidney disease at risk of progression. The plan's pharmacy benefit manager reviews the request against internal clinical criteria. Approval or denial typically arrives within 72 hours for standard requests and 24 hours for expedited requests per CMS regulations.

Common PA Criteria

Plans frequently require evidence that the patient has tried and failed (or has a contraindication to) first-line therapy before approving Jardiance. For diabetes, that means documented metformin use. For heart failure, some plans require documentation of guideline-directed medical therapy including an ACE inhibitor or ARB, a beta-blocker, and a mineralocorticoid receptor antagonist before adding an SGLT2 inhibitor. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure recommends SGLT2 inhibitors as a foundational therapy for HFrEF, which gives clinicians a strong basis for PA appeals.

For CKD, PA criteria often align with the EMPA-KIDNEY and DAPA-CKD trial populations: eGFR between 20 and 90 mL/min/1.73 m² with albuminuria. Plans may deny PA if the patient's eGFR falls below 20.

Step Therapy: What Medicare Advantage Plans Require Before Jardiance

Step therapy mandates that a patient try a less expensive medication before the plan will cover a costlier one. For empagliflozin, step therapy rules vary by indication and by plan.

Diabetes Step Therapy

The most common step therapy requirement for type 2 diabetes is a 60-to-90-day trial of metformin (or documented intolerance/contraindication such as eGFR <30 or lactic acidosis history). Some plans add a second step requiring a sulfonylurea or DPP-4 inhibitor before authorizing an SGLT2 inhibitor. This two-step requirement is becoming less common as clinical guidelines from the American Diabetes Association Standards of Care 2024 increasingly recommend SGLT2 inhibitors as second-line agents for patients with established cardiovascular disease or CKD, regardless of A1C.

Heart Failure and CKD Step Therapy

For heart failure and CKD indications, step therapy requirements are less standardized. The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg or 25 mg reduced cardiovascular death by 38% compared to placebo in patients with type 2 diabetes and established cardiovascular disease over a median follow-up of 3.1 years [1]. This landmark result, published in the New England Journal of Medicine in 2015, shifted SGLT2 inhibitors from glucose-lowering agents to cardiovascular protectants.

Plans that still impose step therapy for heart failure are often overridden at the PA stage when the prescriber cites guideline-concordant therapy. If your plan denies Jardiance for heart failure and demands a step through another drug class, your physician can file a formulary exception request citing the AHA/ACC/HFSA heart failure guideline.

What Jardiance Costs on Medicare Advantage

The manufacturer list price for Jardiance sits near $680 per month. Your actual out-of-pocket cost depends on your plan's tier placement, your current spending phase in the Part D benefit structure, and whether you qualify for Extra Help (Low-Income Subsidy).

The Part D Benefit Phases

Medicare Part D has four cost-sharing phases in 2026. During the deductible phase (up to $590 in 2026), you pay full negotiated price. In the initial coverage phase, you pay your tier-based copay or coinsurance. The coverage gap ("donut hole") was effectively closed by the Inflation Reduction Act (IRA), which capped out-of-pocket Part D spending at $2,000 per year starting in 2025 per CMS guidance. Once you hit that $2,000 cap, you pay $0 for the rest of the year.

Real-World Cost Examples

On a Tier 3 plan with a $42 copay, a patient filling Jardiance 12 months would pay roughly $504 annually (assuming the deductible was already met). On a Tier 4 plan with $95 copay, the annual cost reaches $1,140 before hitting the $2,000 cap. Either way, the IRA cap means no Medicare Advantage enrollee should pay more than $2,000 total across all Part D drugs in a calendar year.

Manufacturer Savings Cards and Medicare

Federal anti-kickback statutes prohibit Medicare beneficiaries from using manufacturer copay cards or savings programs. The Boehringer Ingelheim Jardiance Savings Card, which can reduce copays to as low as $10 for commercially insured patients, cannot be applied to any Medicare plan. This is a legal restriction, not a plan-level policy.

Patients who need financial assistance should ask about the Boehringer Ingelheim Cares Foundation patient assistance program, which provides free medication to Medicare patients who meet income thresholds (generally at or below 400% of the federal poverty level). The FDA-approved prescribing information for Jardiance lists the manufacturer contact for patient support programs.

How to Appeal a Medicare Advantage Denial for Jardiance

A denied PA request does not end the conversation. Medicare Advantage plans must offer a structured appeals process, and success rates on appeal are higher than many patients expect.

Level 1: Plan-Level Redetermination

File within 60 days of the denial. Your physician submits a letter of medical necessity explaining why Jardiance is required, citing the specific clinical indication, relevant trial data (EMPA-REG OUTCOME [1], EMPEROR-Preserved [2], EMPA-KIDNEY [3]), and any failed step-therapy agents. Plans must respond within 7 days for standard appeals or 72 hours for expedited appeals.

Level 2: Independent Review Organization (IRO)

If the plan upholds the denial, the case automatically moves to an IRO. The IRO is an independent body contracted by CMS. Response time is 7 days standard, 72 hours expedited.

Level 3: MAXIMUS Federal External Review

Denied again? The case goes to MAXIMUS, the federal contractor that handles Medicare Part C and D appeals. At this stage, cases with strong clinical justification frequently overturn prior denials. The MAXIMUS filing must occur within 60 days of the IRO decision.

Tips for a Successful Appeal

Keep copies of all lab work (A1C, eGFR, UACR, BNP or NT-proBNP for heart failure), prior medication trials and outcomes, and the specific guideline recommendation your physician is citing. A peer-to-peer review between your prescriber and the plan's medical director can resolve many denials before they reach the formal appeal stage. Ask your doctor's office to request a peer-to-peer within 24 hours of receiving the initial denial.

Jardiance Coverage by Indication: What Medicare Will and Will Not Pay For

Medicare Advantage covers Jardiance for its three FDA-approved indications. The boundaries are firm.

Type 2 Diabetes Mellitus

Covered. Empagliflozin 10 mg and 25 mg are both FDA-approved as adjuncts to diet and exercise for glycemic control in type 2 diabetes. The EMPA-REG OUTCOME trial showed that beyond glucose reduction, empagliflozin reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 14% (HR 0.86, 95% CI 0.74 to 0.99, P=0.04) in patients with established atherosclerotic cardiovascular disease [1].

Heart Failure

Covered. The EMPEROR-Reduced trial (N=3,730) found empagliflozin 10 mg reduced the composite of cardiovascular death or heart failure hospitalization by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) [2]. EMPEROR-Preserved (N=5,988) extended that benefit to HFpEF, with a 21% reduction in the same composite endpoint per results published in the NEJM.

Chronic Kidney Disease

Covered. The EMPA-KIDNEY trial (N=6,609) demonstrated a 28% reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) [3]. This trial included patients without diabetes, broadening the coverage basis.

Weight Loss

Not covered. CMS rules explicitly exclude Part D coverage for drugs prescribed solely for weight loss. Empagliflozin does produce modest weight reduction (approximately 2 to 3 kg in clinical trials), but this is considered a secondary effect, not an approved indication. Any PA request listing weight management as the primary reason will be denied, and that denial is not appealable on clinical grounds.

Comparing Jardiance to Other Covered SGLT2 Inhibitors on Medicare Advantage

If your plan denies Jardiance or places it on a higher tier, your clinician may suggest switching to another SGLT2 inhibitor with better formulary positioning.

Dapagliflozin (Farxiga)

Farxiga shares the same three indications (type 2 diabetes, heart failure, CKD) and has comparable trial evidence from DECLARE-TIMI 58, DAPA-HF, and DAPA-CKD. Some Medicare Advantage plans prefer Farxiga due to different rebate agreements with AstraZeneca. The DAPA-CKD trial results showed a 39% reduction in kidney disease progression.

Canagliflozin (Invokana)

Invokana carries FDA approval for type 2 diabetes and diabetic kidney disease but not for heart failure as a standalone indication. The CREDENCE trial demonstrated renal benefits, but a higher signal for lower-limb amputation in the earlier CANVAS program led some clinicians to reserve canagliflozin for patients without peripheral vascular disease.

Ertugliflozin (Steglatro)

Ertugliflozin is approved only for type 2 diabetes. The VERTIS CV trial did not demonstrate cardiovascular superiority over placebo, making it a weaker choice for patients with established heart or kidney disease. Some plans place ertugliflozin on a lower tier due to its narrower indication profile.

Synjardy and Combination Products

Synjardy (empagliflozin/metformin) and Synjardy XR may have different formulary placement than standalone Jardiance. Some Medicare Advantage plans prefer the combination product because it reduces pill burden and may carry a lower copay than filling two separate prescriptions. Ask your pharmacist to run both configurations through your plan's formulary to compare costs.

The ADA Standards of Care support early combination therapy in patients with A1C 1.5% or more above target, which can justify a PA request for Synjardy as first-line dual therapy.

Annual Enrollment Period: Your Best Window to Optimize Coverage

Medicare Advantage plans can change formulary placement, copay amounts, and PA requirements every plan year. The Annual Enrollment Period (AEP) runs October 15 through December 7 each year. During AEP, you can switch to a Medicare Advantage plan that offers better Jardiance coverage, a lower tier, or fewer PA barriers.

Use the Medicare Plan Finder tool to enter your zip code and medications. The tool shows estimated annual out-of-pocket costs for each available plan, including Jardiance at your specific dose. Comparing three to five plans takes roughly 15 minutes and can save hundreds of dollars annually.